Company Encyclopedia
View More
name
Vivos Therapeutics
VVOS.US
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
374.78 B
VVOS.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
Health Care ServicesIndustry
Industry Ranking69/80
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-262.05%E
    • Profit Margin-99.50%E
    • Gross Margin55.24%B
  • Growth ScoreC
    • Revenue YoY2.65%C
    • Net Profit YoY-18.91%D
    • Total Assets YoY64.33%A
    • Net Assets YoY-27.79%E
  • Cash ScoreD
    • Cash Flow Margin-100.50%D
    • OCF YoY2.65%C
  • Operating ScoreB
    • Turnover0.69B
  • Debt ScoreE
    • Gearing Ratio82.40%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Vivos Therapeutics | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 6.783 M

    LB filings·
    US
    VVOS
    -4.45%
    LB filings·
    US
    VVOS
    -4.45%

    Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025

    Vivos Therapeutics Inc. reported a 78% sequential revenue growth in Q3 2025, with a 76% increase year-over-year. This growth is attributed to a strategic shift from dental industry distribution to acquiring medical sleep practices, highlighted by acquiring The Sleep Center of Nevada in June 2025. Detailed financial results are available in their Form 10-Q filed with the SEC.

    Reuters·
    US
    VVOS
    -4.45%
    Reuters·
    US
    VVOS
    -4.45%

    Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition

    Vivos Therapeutics' Q3 2025 revenue rose 76% year-over-year, driven by the acquisition of The Sleep Center of Nevada (SCN). Despite a decline in gross margin to 58% and a 74% increase in operating expenses, the company plans to expand its sleep center model. Analysts rate the stock as a 'buy' with a 12-month price target of $6.50, 62% above its current price.

    Reuters·
    US
    VVOS
    -4.45%
    Reuters·
    US
    VVOS
    -4.45%

    Vivos Therapeutics Q3 Net Income USD -5.4 Million

    Nov 19 (Reuters) - Vivos Therapeutics Q3 operating income USD -4.734 million. * Q3 gross profit USD 3.937 million

    Reuters·
    US
    VVOS
    -4.45%
    Reuters·
    US
    VVOS
    -4.45%

    Vivos Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 6.783 M

    LB filings·
    US
    VVOS
    -4.45%
    LB filings·
    US
    VVOS
    -4.45%